Physician profile
Rhett L Brown
NPI 1942235031
$18,097.08
in general payments reported to CMS, 2019-2025
24 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2022: $308 · 2023: $62.93 · 2024: $370 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $2,262 · Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,350.00 |
| Travel and Lodging | $2,261.94 |
| Food and Beverage | $2,027.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16,580.05 | 2019-2025 | Yeztugo, Descovy |
| Novo Nordisk INC | $540.83 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Viiv Healthcare Company | $127.86 | 2022-2025 | Apretude, Cabenuva, Rukobia |
| Pfizer INC. | $118.51 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $114.31 | 2022-2025 | Capvaxive, Pifeltro, Gardasil 9 |
| Lilly USA, LLC | $87.09 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $70.30 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $54.80 | 2025 | Keveyis |
| Exact Sciences Corporation | $51.04 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $44.77 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.67 | 2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $27.46 | 2024 | |
| Amgen INC. | $26.09 | 2025 | Repatha |
| Mayne Pharma Commercial LLC | $25.06 | 2024 | |
| Seqirus USA INC | $24.99 | 2025 | Fluad, Flucelvax |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.08 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $22.02 | 2025 | Qelbree |
| Mylan Specialty L.P. | $21.74 | 2019 | |
| Dexcom, INC. | $20.39 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $19.51 | 2025 | Airsupra |
| Organon LLC | $18.94 | 2022 | |
| Axsome Therapeutics, INC. | $17.77 | 2025 | Symbravo |
| Abbvie INC. | $17.27 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.53 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhett Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.